Literature DB >> 30385039

An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study).

Philippe Rémy1, Vincent Audard1, Pierre André Natella2, Gaëlle Pelle3, Bertrand Dussol4, Helene Leray-Moragues5, Cecile Vigneau6, Khedidja Bouachi1, Jacques Dantal7, Laurence Vrigneaud8, Alexandre Karras9, Frank Pourcine1, Philippe Gatault10, Philippe Grimbert1, Nawelle Ait Sahlia11, Anissa Moktefi12, Eric Daugas13, Claire Rigothier14, Sylvie Bastuji-Garin2, Dil Sahali15.   

Abstract

First-line therapy of minimal change nephrotic syndrome (MCNS) in adults is extrapolated largely from pediatric studies and consists of high-dose oral corticosteroids. We assessed whether a low corticosteroid dose combined with mycophenolate sodium was superior to a standard oral corticosteroid regimen. We enrolled 116 adults with MCNS in an open-label randomized controlled trial involving 32 French centers. Participants randomly assigned to the test group (n=58) received low-dose prednisone (0.5 mg/kg/day, maximum 40 mg/day) plus enteric-coated mycophenolate sodium 720 mg twice daily for 24 weeks; those who did not achieve complete remission after week 8 were eligible for a second-line regimen (increase in the prednisone dose to 1 mg/kg/day with or without Cyclosporine). Participants randomly assigned to the control group (n=58) received conventional high-dose prednisone (1 mg/kg/day, maximum 80 mg/day) for 24 weeks. The primary endpoint of complete remission after four weeks of treatment was ascertained in 109 participants, with no significant difference between the test and control groups. Secondary outcomes, including remission after 8 and 24 weeks of treatment, did not differ between the two groups. During 52 weeks of follow-up, MCNS relapsed in 15 participants (23.1%) who had achieved the primary outcome. Median time to relapse was similar in the test and control groups (7.1 and 5.1 months, respectively), as was the incidence of serious adverse events. Five participants died from hemorrhage (n=2) or septic shock (n=3), including 2 participants in the test group and 3 in the control group. Thus, in adult patients, treatment with low-dose prednisone plus enteric-coated mycophenolate sodium was not superior to a standard high-dose prednisone regimen to induce complete remission of MCNS.
Copyright © 2018 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  clinical trial; idiopathic nephrotic syndrome; mycophenolate; steroids

Mesh:

Substances:

Year:  2018        PMID: 30385039     DOI: 10.1016/j.kint.2018.07.021

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

Review 1.  Interventions for minimal change disease in adults with nephrotic syndrome.

Authors:  Karolis Azukaitis; Suetonia C Palmer; Giovanni Fm Strippoli; Elisabeth M Hodson
Journal:  Cochrane Database Syst Rev       Date:  2022-03-01

Review 2.  Podocytopathies.

Authors:  Jeffrey B Kopp; Hans-Joachim Anders; Katalin Susztak; Manuel A Podestà; Giuseppe Remuzzi; Friedhelm Hildebrandt; Paola Romagnani
Journal:  Nat Rev Dis Primers       Date:  2020-08-13       Impact factor: 52.329

3.  Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults.

Authors:  Ho Jun Chin; Dong-Wan Chae; Yong Chul Kim; Won Suk An; ChunGyoo Ihm; Dong-Chan Jin; Sung Gyun Kim; Yong-Lim Kim; Yong-Soo Kim; Yoon-Goo Kim; Ho Seok Koo; Jung Eun Lee; Kang Wook Lee; Jieun Oh; Jung Hwan Park; Hongsi Jiang; Hyuncheol Lee; Sang Koo Lee
Journal:  J Am Soc Nephrol       Date:  2020-11-09       Impact factor: 10.121

4.  Apheresis in Adult With Refractory Idiopathic Nephrotic Syndrome on Native Kidneys.

Authors:  Léa Moret; Alexandre Ganea; Myriam Dao; Aurélie Hummel; Bertrand Knebelman; Jean François Subra; Johan Noble; Christophe Mariat; Noémie Jourde-Chiche; Fatouma Toure; Cyril Garrouste; Charlotte Laurent; Lacraz Adeline; Yahsou Delmas; Alexandre Cez; Olivier Fritz; Christiane Mousson; Lise Marie Pouteau; Olivier Moranne; Jean-Michel Halimi; Vincent Audard
Journal:  Kidney Int Rep       Date:  2021-05-06

Review 5.  B-Cell Dysregulation in Idiopathic Nephrotic Syndrome: What We Know and What We Need to Discover.

Authors:  Manuela Colucci; Julie Oniszczuk; Marina Vivarelli; Vincent Audard
Journal:  Front Immunol       Date:  2022-01-24       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.